Dabigatran, bleeding, and the regulators

@article{Moore2014DabigatranBA,
  title={Dabigatran, bleeding, and the regulators},
  author={T. Moore and M. Cohen and D. Mattison},
  journal={BMJ : British Medical Journal},
  year={2014},
  volume={349}
}
  • T. Moore, M. Cohen, D. Mattison
  • Published 2014
  • Medicine
  • BMJ : British Medical Journal
  • Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of dabigatran 
    73 Citations
    Dabigatran: how the drug company withheld important analyses
    • D. Cohen
    • Medicine
    • BMJ : British Medical Journal
    • 2014
    • 109
    • PDF
    New oral anticoagulants: dosing and monitoring
    • 5
    News and views The Dabigatran debate
    The Dabigatran debate
    • 3
    • PDF
    Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient
    • 22
    Bleeding and the new anticoagulants: strategies and concerns.
    • 2
    • PDF

    References

    SHOWING 1-10 OF 27 REFERENCES
    Dabigatran and postmarketing reports of bleeding.
    • 358
    • PDF
    Dabigatran versus warfarin in patients with atrial fibrillation.
    • 2,896
    • PDF
    Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    • 57
    Newly identified events in the RE-LY trial.
    • 693
    • PDF
    Dabigatran versus warfarin in patients with mechanical heart valves.
    • 622
    • PDF